These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 16264108)

  • 1. Renal safety of ibandronate.
    Jackson GH
    Oncologist; 2005; 10 Suppl 1():14-8. PubMed ID: 16264108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of ibandronate in metastatic bone disease: review of clinical data.
    Bell R
    Oncologist; 2005; 10 Suppl 1():8-13. PubMed ID: 16264107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisphosphonate treatment recommendations for oncologists.
    von Moos R
    Oncologist; 2005; 10 Suppl 1():19-24. PubMed ID: 16264109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ibandronate: its role in metastatic breast cancer.
    Cameron D; Fallon M; Diel I
    Oncologist; 2006; 11 Suppl 1():27-33. PubMed ID: 16971737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ibandronate: efficacy in the treatment of metastatic bone disease.
    Diel IJ
    Future Oncol; 2005 Oct; 1(5):593-607. PubMed ID: 16556036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous ibandronate does not affect time to renal function deterioration in patients with skeletal metastases from breast cancer: phase III trial results.
    Body JJ; Diel IJ; Tripathy D; Bergstrom B
    Eur J Cancer Care (Engl); 2006 Jul; 15(3):299-302. PubMed ID: 16882128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal safety and pharmacokinetics of ibandronate in multiple myeloma patients with or without impaired renal function.
    Bergner R; Henrich DM; Hoffmann M; Honecker A; Mikus G; Nauth B; Nagel D; Uppenkamp M
    J Clin Pharmacol; 2007 Aug; 47(8):942-50. PubMed ID: 17615253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical and clinical efficacy of the bisphosphonate ibandronate in cancer treatment.
    Bauss F; Bergström B
    Curr Clin Pharmacol; 2008 Jan; 3(1):1-10. PubMed ID: 18690873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review of ibandronate in the treatment of metastatic bone disease: experience from phase III trials.
    Tripathy D; Body JJ; Bergström B
    Clin Ther; 2004 Dec; 26(12):1947-59. PubMed ID: 15823760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone pain reduction in patients with metastatic breast cancer treated with ibandronate-results from a post-marketing surveillance study.
    Diel IJ; Kurth AH; Sittig HB; Meden H; Maasberg M; Sandermann A; Bergner R
    Support Care Cancer; 2010 Oct; 18(10):1305-12. PubMed ID: 20151162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal safety of ibandronate 6 mg infused over 15 min versus 60 min in breast cancer patients with bone metastases: a randomized open-label equivalence trial.
    Pivot X; Lortholary A; Abadie-Lacourtoisie S; Mefti-Lacheraf F; Pujade-Lauraine E; Lefeuvre C; Letessier S; Morvan P; Dür C; Frimat L
    Breast; 2011 Dec; 20(6):510-4. PubMed ID: 21727006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Profiling the safety and tolerability of bisphosphonates.
    Body JJ; Diel I; Bell R
    Semin Oncol; 2004 Oct; 31(5 Suppl 10):73-8. PubMed ID: 15490380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ibandronate is effective in preventing skeletal events in patients with bone metastases from colorectal cancer.
    Heras P; Karagiannis S; Kritikos K; Hatzopoulos A; Mitsibounas D
    Eur J Cancer Care (Engl); 2007 Nov; 16(6):539-42. PubMed ID: 17944770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ibandronate to treat skeletal-related events and bone pain in metastatic bone disease or multiple myeloma: a meta-analysis of randomised clinical trials.
    Geng CJ; Liang Q; Zhong JH; Zhu M; Meng FY; Wu N; Liang R; Yuan BY
    BMJ Open; 2015 Jun; 5(6):e007258. PubMed ID: 26038356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse effects of bisphosphonates: current issues.
    Diel IJ; Bergner R; Grötz KA
    J Support Oncol; 2007; 5(10):475-82. PubMed ID: 18240669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records review.
    Diel IJ; Weide R; Köppler H; Antràs L; Smith M; Green J; Wintfeld N; Neary M; Duh MS
    Support Care Cancer; 2009 Jun; 17(6):719-25. PubMed ID: 19089462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of difference in acute nephrotoxicity of intravenous bisphosphonates zoledronic acid and ibandronate in women with breast cancer and bone metastases.
    Luedders DW; Steinhoff J; Thill M; Rody A; Bohlmann MK
    Anticancer Res; 2015 Mar; 35(3):1797-802. PubMed ID: 25750345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid administration of ibandronate does not affect renal functioning: evidence from clinical studies in metastatic bone disease and hypercalcaemia of malignancy.
    Pecherstorfer M; Diel IJ
    Support Care Cancer; 2004 Dec; 12(12):877-81. PubMed ID: 15372222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term renal safety profile of ibandronate 6 mg infused over 15 minutes.
    von Moos R; Caspar CB; Steiner R; Angst R; Inauen R; Schmieding K; Thürlimann B
    Onkologie; 2010; 33(8-9):447-50. PubMed ID: 20838060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bisphosphonates in metastatic bone disease: renal safety matters.
    Body JJ
    Oncologist; 2005; 10 Suppl 1():1-2. PubMed ID: 16264105
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.